Pre-Made Modakafusp Alfa Biosimilar, Fusion Protein targeting CD38 fused with human IFNA2 (interferon alpha 2) *b (R46,H57) 24-188: Recombinant therapeutic protein targeting ADPRC 1/ADPRC1 for drug discovery and mechanism of action (MOA) research

Pre-Made Modakafusp Alfa Biosimilar, Fusion Protein targeting CD38 fused with human IFNA2 (interferon alpha 2) *b (R46,H57) 24-188: Recombinant therapeutic protein targeting ADPRC 1/ADPRC1 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Modakafusp alfa is a first-in-class immunocytokine designed to deliver interferon alpha-2b (IFNα2b) to CD38+ cells. It consists of two attenuated IFNα2b molecules genetically fused to the Fc portion of a humanized, anti-CD38, IgG4 monoclonal antibody (mAb). The specificity for CD38 and reduced IFN receptor binding affinity of the attenuated IFNα2b molecules significantly reduces the potential for off-target binding and toxicity. Modakafusp alfa is a novel candidate for the treatment of relapsed/refractory multiple myeloma.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-917-1mg	1mg	3090
GMP-Bios-INN-917-10mg	10mg	Inquiry
GMP-Bios-INN-917-100mg	100mg	Inquiry
GMP-Bios-INN-917-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Modakafusp Alfa Biosimilar, Fusion Protein targeting CD38 fused with human IFNA2 (interferon alpha 2) *b (R46,H57) 24-188: Recombinant therapeutic protein targeting ADPRC 1/ADPRC1
INN Name	Modakafusp Alfa
Target	CD38
Format	Fusion Protein
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG4 - kappa
VD LC	IgG4 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Takeda Pharmaceuticals U.S.A., Inc. (Deerfield IL USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0